$CXT

Fund Update: New $93.1M $CXT stock position opened by DEPRINCE RACE & ZOLLO INC

DEPRINCE RACE & ZOLLO INC opened a $93.1M position in CXT, according to a recent SEC 13F filing. 179 institutional investors increased their CXT holdings, while 201 decreased theirs in Q2 2026. Notable moves include additions by BLACKROCK and INVESCO, and removals by WELLINGTON MANAGEMENT and CAPITAL INTERNATIONAL.

Original reporting
Published Aug 20, 2026, 3:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 10:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fund Update: New $93.1M $CXT stock position opened by DEPRINCE RACE & ZOLLO INC — source image
Decision brief

The 30-second read

$CXTBullishMed
01

Why it matters

The disclosed stake may attract other investors and increase liquidity for CXT.

02

Market read

Fresh 13F data provides actionable insight into institutional sentiment toward CXT.

03

What to watch

Potential upcoming clinical data or regulatory events for CXT not disclosed.

Relevance 8/10Novelty 7/10Timing: post‑filing Aug 20 2026

Background

13F filings reveal institutional holdings; new large positions can influence market perception.

Company-level read

Ticker impact

$CXTBullishMedium confidence
Context

DEPRINCE RACE & ZOLLO INC disclosed a new $93.1M long position in CXT via its Q2 2026 13F filing.

Expected impact

Potential modest upside as the market absorbs the new demand.

Evidence & confidence

The filing is the first public disclosure of a sizable $93M stake, indicating fresh interest from a hedge fund.

Market effects

May highlight growing interest in the biotech/health‑care sector.

Limited to US equity markets where CXT trades.

Low; primarily affects investors tracking CXT.

Counterpoint

The stake could be a short‑term tactical move; price may not sustain.

Key entities

  • DEPRINCE RACE & ZOLLO INC

    Institutional investor filing a 13F.

  • CXT

    Publicly traded company receiving a $93M stake.

Related articles

$CXTLow

Crane NXT (CXT) Could Be 25% Below Fair Value As New President Takes Key Role

Crane NXT (CXT) appointed Jason Lund as President of Crane Payment Innovations and Group President of its Detection and Traceability Technologies segment. The stock trades at $50.20, with a 90-day return of 23.07% but a 1-year return of -18.55%. Analysts suggest it may be 25% undervalued at $66.83, citing growth potential in authentication and cybersecurity, though digital payment shifts and acquisition risks remain.

$CXTMedAI 8/10

Crane NXT (CXT) Q2 2026 Earnings Call Transcript

Crane NXT (CXT) reported Q2 2026 net sales of $493.2M, up 22% year over year, and adjusted EPS of $1.10, up 13.4%. Adjusted EBITDA was $115.5M (23.4% margin). Management cited Antares Vision acquisition contributions and organic growth, record SAT backlog, and raised full-year adjusted EPS guidance to $4.22-$4.42.

$CXTMed

Crane NXT Q2 Earnings Call Highlights

Crane NXT (NYSE:CXT) reported Q2 SAT sales of $227 million, up about 17% Y/Y, with adjusted EBITDA of $59 million and a 26% margin. Management expects full-year SAT sales growth of high-single-digit to low-double-digit and mid-teens authentication EBITDA margin by 2026. DTT sales rose 26% to $267 million. Net leverage was ~2.7x.

$CXTHigh

Crane NXT, Co. (CXT): Results of Operations and Financial Condition

Crane NXT, Co. (CXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-pressreleasexq2.htm EX-99.1 Document Exhibit 99.1 Contact: Matt Roache Vice President, Investor Relations +1-781-864-4730 matthew.roache@cranenxt.com Crane NXT Reports Second Quarter 2026 Results Delivers Sales Growth of 22%; Raises Full Year Adjusted EPS Gui

$SPCXMed

Billionaire Ron Baron makes $24.9 billion bet on controversial giant

Baron Capital's Q2 13F filing reveals a $24.9 billion stake in SpaceX (SPCX), making it 37.38% of its $66.64 billion portfolio. SPCX closed at $136.97, below Baron's average cost of $170.86. SpaceX reported Q2 2026 revenue of $7.8 billion, a 92% YOY increase, and adjusted EBITDA of $3.5 billion, up 191%. Baron's long-term strategy focuses on growth potential, despite short-term volatility and valuation concerns.